JLE

e-VEGF-IMMUNO-actu

MENU

Intérêt des voies immunes en oncologie : naissance ou renaissance de l’immuno-oncologie Volume 11, numéro 1, Janvier 2016

  • [1] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
  • [2] Hanahan D, Weinberg RA. Hallmarks of cancer : the next generation. Cell. 2011;144:646-74.
  • [3] Cheever MA. The prioritization of cancer antigens : a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-37.
  • [4] Schreiber RD. Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-70.
  • [5] Mittal D. New insights into cancer immunoediting and its three components phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.
  • [6] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-8.
  • [7] Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61-73.
  • [8] Wolchok JD. Monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-64.
  • [9] Brahmer AH. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
  • [10] Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
  • [11] Larkin J. Combined and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.